Skandinaviska Enskilda Banken AB publ Has $11.82 Million Position in Insulet Co. (NASDAQ:PODD)

Skandinaviska Enskilda Banken AB publ grew its holdings in Insulet Co. (NASDAQ:PODD - Free Report) by 203.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 44,875 shares of the medical instruments supplier's stock after purchasing an additional 30,102 shares during the period. Skandinaviska Enskilda Banken AB publ owned about 0.06% of Insulet worth $11,820,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. SBI Securities Co. Ltd. acquired a new position in shares of Insulet in the 4th quarter valued at about $36,000. Sumitomo Mitsui DS Asset Management Company Ltd increased its holdings in Insulet by 30.1% in the fourth quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 8,395 shares of the medical instruments supplier's stock worth $2,192,000 after buying an additional 1,942 shares during the last quarter. Fisher Asset Management LLC increased its holdings in Insulet by 0.9% in the third quarter. Fisher Asset Management LLC now owns 351,100 shares of the medical instruments supplier's stock worth $81,719,000 after buying an additional 3,113 shares during the last quarter. Orion Portfolio Solutions LLC increased its holdings in Insulet by 86.2% in the third quarter. Orion Portfolio Solutions LLC now owns 7,826 shares of the medical instruments supplier's stock worth $1,822,000 after buying an additional 3,623 shares during the last quarter. Finally, Nomura Asset Management Co. Ltd. increased its holdings in Insulet by 5.7% in the third quarter. Nomura Asset Management Co. Ltd. now owns 153,416 shares of the medical instruments supplier's stock worth $35,708,000 after buying an additional 8,301 shares during the last quarter.

Remove Ads

Insulet Stock Performance

PODD stock traded up $5.35 during midday trading on Wednesday, hitting $265.82. The stock had a trading volume of 588,392 shares, compared to its average volume of 689,494. The firm has a market capitalization of $18.67 billion, a price-to-earnings ratio of 45.91, a P/E/G ratio of 3.62 and a beta of 1.29. Insulet Co. has a 52 week low of $160.19 and a 52 week high of $289.46. The stock has a 50-day simple moving average of $272.30 and a 200 day simple moving average of $256.12. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21.

Insulet (NASDAQ:PODD - Get Free Report) last issued its earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 EPS for the quarter, topping the consensus estimate of $1.00 by $0.15. The firm had revenue of $597.50 million during the quarter, compared to analysts' expectations of $582.02 million. Insulet had a return on equity of 24.46% and a net margin of 20.19%. As a group, equities research analysts anticipate that Insulet Co. will post 3.92 earnings per share for the current year.

Insider Buying and Selling

In other Insulet news, EVP Eric Benjamin sold 12,394 shares of the stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total transaction of $3,470,320.00. Following the completion of the transaction, the executive vice president now directly owns 11,383 shares in the company, valued at $3,187,240. This represents a 52.13 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.47% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on PODD shares. Piper Sandler upped their target price on Insulet from $285.00 to $310.00 and gave the stock an "overweight" rating in a research report on Friday, February 21st. Royal Bank of Canada started coverage on Insulet in a research report on Thursday, March 6th. They set an "outperform" rating and a $340.00 target price for the company. Stifel Nicolaus upped their target price on Insulet from $245.00 to $293.00 and gave the stock a "hold" rating in a research report on Friday, February 21st. StockNews.com cut Insulet from a "buy" rating to a "hold" rating in a research report on Tuesday, March 4th. Finally, Wells Fargo & Company upped their target price on Insulet from $305.00 to $322.00 and gave the stock an "overweight" rating in a research report on Friday, February 21st. Four research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $292.06.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.